AZEVAN PHARMACEUTICALS INC

Basic Information

116 RESEARCH DR
BETHLEHEM, PA, 18015-4734

Company Profile

n/a

Additional Details

Field Value
DUNS: 604182118
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 7


  1. Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder

    Amount: $141,071.00

    DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as ...

    STTR Phase I 2011 Department of Health and Human Services
  2. New Drugs for Stress-related Affective Illness

    Amount: $1,794,075.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. New Drugs for Stress-related Affective Illness

    Amount: $349,195.00

    DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observ ...

    SBIR Phase I 2010 Department of Health and Human Services
  4. A Potential New Drug for Depression

    Amount: $0.00

    DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered m ...

    SBIR Phase II 2009 Department of Health and Human Services
  5. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $0.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTR Phase I 2002 Department of Health and Human Services
  6. A NEW DRUG FOR DEPRESSION

    Amount: $100,000.00

    Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and h ...

    SBIR Phase I 2002 Department of Health and Human Services
  7. TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION

    Amount: $498,684.00

    Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, terme ...

    STTR Phase II 2002 Department of Health and Human Services
  8. N/A

    Amount: $100,000.00

    N/A

    STTR Phase I 2000 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government